Jaimal Kothari

746 total citations
35 papers, 311 citations indexed

About

Jaimal Kothari is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Jaimal Kothari has authored 35 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 17 papers in Oncology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Jaimal Kothari's work include Multiple Myeloma Research and Treatments (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Protein Degradation and Inhibitors (8 papers). Jaimal Kothari is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Lymphoma Diagnosis and Treatment (13 papers) and Protein Degradation and Inhibitors (8 papers). Jaimal Kothari collaborates with scholars based in United Kingdom, Greece and Canada. Jaimal Kothari's co-authors include Karthik Ramasamy, Richard Haynes, Maria Fernanda Soares, Ankur Jain, A. E. Taylor, Roberto Stasi, Nichola Cooper, Marie Scully, Siobhan McGuckin and Shirley D’Sa and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jaimal Kothari

33 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaimal Kothari United Kingdom 11 146 131 122 101 94 35 311
Mercedes Gironella Spain 11 199 1.4× 71 0.5× 89 0.7× 149 1.5× 135 1.4× 46 355
Carlos E. Bueso-Ramos United States 6 149 1.0× 147 1.1× 171 1.4× 73 0.7× 109 1.2× 12 334
David H. Vesole United States 9 164 1.1× 196 1.5× 144 1.2× 195 1.9× 178 1.9× 30 444
Christos Karkantaris Greece 7 144 1.0× 225 1.7× 194 1.6× 166 1.6× 59 0.6× 9 402
Amie Fonder United States 8 112 0.8× 110 0.8× 194 1.6× 63 0.6× 81 0.9× 31 291
S. Mellou Greece 8 100 0.7× 41 0.3× 89 0.7× 85 0.8× 123 1.3× 12 298
Marzia Defina Italy 10 271 1.9× 83 0.6× 113 0.9× 61 0.6× 43 0.5× 35 355
Catia Bigazzi Italy 11 181 1.2× 148 1.1× 184 1.5× 121 1.2× 85 0.9× 16 368
Lidija Čevreska North Macedonia 9 147 1.0× 153 1.2× 169 1.4× 104 1.0× 31 0.3× 40 410
Vít Campr Czechia 10 81 0.6× 210 1.6× 121 1.0× 147 1.5× 39 0.4× 46 328

Countries citing papers authored by Jaimal Kothari

Since Specialization
Citations

This map shows the geographic impact of Jaimal Kothari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaimal Kothari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaimal Kothari more than expected).

Fields of papers citing papers by Jaimal Kothari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaimal Kothari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaimal Kothari. The network helps show where Jaimal Kothari may publish in the future.

Co-authorship network of co-authors of Jaimal Kothari

This figure shows the co-authorship network connecting the top 25 collaborators of Jaimal Kothari. A scholar is included among the top collaborators of Jaimal Kothari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaimal Kothari. Jaimal Kothari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281. 3 indexed citations
2.
Agarwal, Gaurav, Lisa Ferguson, Jaimal Kothari, et al.. (2023). Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients. Blood. 142(Supplement 1). 644–644. 1 indexed citations
3.
Khwaja, Jahanzaib, Helen O. McCarthy, Jaimal Kothari, et al.. (2023). The Rory Morrison WMUK Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorder. British Journal of Haematology. 201(5). 905–912. 4 indexed citations
4.
5.
Khwaja, Jahanzaib, Helen O. McCarthy, Jaimal Kothari, et al.. (2022). Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry. SHILAP Revista de lepidopterología. 4(1). 221–225. 5 indexed citations
6.
Vallance, Grant, et al.. (2021). Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort. Journal of Oncology Pharmacy Practice. 29(2). 299–304. 2 indexed citations
7.
Desborough, Michael, et al.. (2021). Acquired platelet dysfunction in newly diagnosed myeloma. SHILAP Revista de lepidopterología. 2(1). 17–19. 1 indexed citations
8.
Eyre, Toby A., William Wilson, Amy A. Kirkwood, et al.. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances. 5(8). 2229–2236. 19 indexed citations
9.
Watts, Eleanor L., Aurora Perez‐Cornago, Jaimal Kothari, et al.. (2020). Hematologic Markers and Prostate Cancer Risk: A Prospective Analysis in UK Biobank. Cancer Epidemiology Biomarkers & Prevention. 29(8). 1615–1626. 19 indexed citations
10.
Sharpley, Faye, Grant Vallance, Toby A. Eyre, et al.. (2020). Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS ONE. 15(2). e0229469–e0229469. 4 indexed citations
11.
Terpos, Evangelos, Karthik Ramasamy, Jiří Minařík, et al.. (2020). Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology. 99(5). 1049–1061. 26 indexed citations
12.
Kishore, Bhuvan, Matthew Jenner, Kevin Boyd, et al.. (2020). Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leukemia & lymphoma. 62(6). 1396–1404. 5 indexed citations
13.
Panitsas, Fotios, Faye Sharpley, Alexandros Rampotas, et al.. (2020). Myeloma care adaptations in the UK during SARS‐CoV‐2 pandemic: Challenges and measurable outcomes. European Journal Of Haematology. 105(5). 662–666. 2 indexed citations
14.
Jain, Ankur, et al.. (2019). Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Advances. 3(15). 2409–2423. 39 indexed citations
15.
Vallance, Grant, et al.. (2018). Clinical outcomes of bortezomib-based therapy in myeloma. PLoS ONE. 13(12). e0208920–e0208920. 5 indexed citations
16.
Taylor, A. E., Siobhan McGuckin, Jaimal Kothari, et al.. (2015). Mycophenolate mofetil therapy for severe immune thrombocytopenia. British Journal of Haematology. 171(4). 625–630. 52 indexed citations
17.
Kothari, Jaimal, Alison Thomas, & Anthony P. Goldstone. (2014). Pseudohyponatraemia due to L-asparaginase-associated dyslipidaemia in T-cell lymphoblastic lymphoma. BMJ Case Reports. 2014. bcr2013202829–bcr2013202829. 4 indexed citations
18.
Kothari, Jaimal, et al.. (2014). Cryoglobulinaemia identified by repeated analytical failure of laboratory tests. The Lancet. 383(9914). 382–382. 1 indexed citations
19.
Kothari, Jaimal, Karl S. Peggs, Kirsty Thomson, et al.. (2011). Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure. Blood. 118(21). 2025–2025. 1 indexed citations
20.
Sehn, Laurie H., Sarit Assouline, Douglas A. Stewart, et al.. (2009). A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease.. Blood. 114(22). 934–934. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mercedes Gironella Breakdown of academic impact, for papers by Carlos E. Bueso-Ramos Breakdown of academic impact, for papers by David H. Vesole Breakdown of academic impact, for papers by Christos Karkantaris Breakdown of academic impact, for papers by Amie Fonder Breakdown of academic impact, for papers by S. Mellou Breakdown of academic impact, for papers by Marzia Defina Breakdown of academic impact, for papers by Catia Bigazzi Breakdown of academic impact, for papers by Lidija Čevreska Breakdown of academic impact, for papers by Vít Campr
Rankless by CCL
2026